Roth Capital Partners initiated coverage of Moleculin Biotech (NASDAQ:MBRX) with a “buy” rating and $8 price target. The stock closed at $1.69 on Dec. 20.Read More
Stifel raised its price target for GlycoMimetics (NASDAQ:GLYC) to $23 from $17 after the company presented incremental Phase 1/2 data for GMI-1271 in both relapsed/refractory (R/R) and newly-diagnosed AML patients. The stock closed at $14.32 on Dec. 11.Read More
Mateon Therapeutics (OTCQX:MATN) announced updated data from the fifth dose cohort of OX1222, a Phase 1b dose-ranging study of OXi4503 in combination with cytarabine in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS).Read More
Roth Capital Partners launched coverage of Syros Pharmaceuticals (NASDAQ:SYRS) with a “neutral” rating and price target of $16. The stock closed at $16.51 on Oct.23.Read More
Mateon Therapeutics (OTCQX:MATN) terminated its Phase 2/3 FOCUS after a third scheduled interim analysis of CA4P in combination with bevacizumab (Avastin) and physician’s choice chemotherapy in patients with platinum-resistant ovarian cancer because of a clear efficacy signal.Read More
Ladenburg Thalmann initiated coverage of Bellicum Pharmaceuticals (NASDAQ:BLCM) with a “buy” rating and $31 price target. The stock closed at $19.16 on Nov. 29.Read More
Roth Capital Partners initiated coverage of Actinium Pharmaceuticals (NYSE MKT:ATNM) with a “buy” rating and $5 price target. The stock closed at $1.66 on Wednesday.
“We believe it is an opportune time to explore the investment case of Actinium based on the late-stage nature of the lead asset, addressing unmet medical needs, clinical data in hand, and a broad set of upcoming catalysts,” writes analyst Joseph Pantginis.Read More
Maxim Group lowered its price target for Bio-Path Holdings (NASDAQ:BPTH) to $2 from $5, citing the company’s data trough ahead. The stock was changing hands at $1.72 on Wednesday afternoon.
Analyst Jason McCarthy writes that Bio-Path is funded through the next inflection point, proof-of-concept (POC) Phase 2 data for lead antisense drug, BP1001, in AML. Data could be released in late 2017, depending on the speed of enrollment. The first patient should be enrolled soon, with clinical sites now open.Read More
Roth Capital Partners has raised its price target for Celator Pharmaceuticals (NASDAQ:CPXX) to $26 from $22, after the company’s Vyxeos drug candidate received breakthrough therapy designation from the FDA. The stock closed at $15.07 on Wednesday
“This is an important next step for Vyxeos on the path to what we believe is likely approval,” writes analyst Joseph Pantginis.Read More
Closely-held BioSight has closed an investment of $13-million led by Mori Arkin’s pharmaceutical investment firm, Arkin Holdings, and the U.S.-based venture firm, Primera Capital.
Proceeds will be used for a multi-center, Phase 2b clinical trial with the company’s lead product, Astarabine, for the treatment of acute myeloid leukemia (AML).Read More
Stifel has initiated coverage of Celator Pharmaceuticals (NASDAQ:CPXX) with a “buy” rating and a 12-month target price of $23. The stock closed at $15.52 on Thursday.
Analyst Stephen Willey writes that recently-announced Phase 3 data, demonstrating Vyxeos confers a statistically-significant improvement in overall survival versus traditional cytarabine/daunorubicin chemotherapy (“7+3”) in patients aged 60-to-75 with high-risk/secondary acute myeloid leukemia (AML), represents the first meaningful therapeutic advancement in AML since conventional “7+3” chemotherapy became the backbone of intensive induction therapy more than 40 years ago.Read More
Closely-held BioSight has completed patient treatment in its ongoing Phase 1/2a clinical study of Astarabine in acute leukemia patients and expects to report final results in coming months.
The Phase 1/2a trial is an open-label study to evaluate the safety and efficacy of Astarabine as single agent in adults with acute myeloid leukemia (AML) and relapsed/refractory acute lymphoblastic leukemia (ALL).Read More
Rodman & Renshaw has launched coverage of Bio-Path Holdings (NASDAQ:BPTH) with a “buy” rating and a 12-month price target of $5. The stock closed at $2.76 on Monday.
“In our view, Bio-Path’s unique liposomal delivery of antisense DNA has the potential to significantly improve treatment outcomes in elderly patients (≥60 years) with acute myeloid leukemia (AML),” writes analyst Raghuram Selvaraju.Read More
H.C. Wainwright has launched coverage of Actinium Pharmaceuticals (NASDAQ:ATNM) with a “buy” rating and a price target of $8. The stock closed at $1.98 on Friday.
"We believe that due to a long history of pivotal failures on top of a scarcity of treatment options, AML is likely to start enjoying some regulatory slack over the next few years, with Actinium well-positioned for value with two pedigreed assets tackling two different stages of the disease,” writes analyst Andrew Fein.Read More